Blockchain Registration Transaction Record

Regentis Biomaterials Targets $3B Knee Cartilage Market with Off-the-Shelf GelrinC(R)

Regentis Biomaterials' GelrinC(R) platform targets $3B knee cartilage market with off-the-shelf, single-step procedure. Clinical data shows 100% greater pain improvement vs microfracture. Phase III trial underway.

This matters because knee cartilage injuries affect millions, often requiring painful, costly procedures with long recoveries. GelrinC(R) offers a simpler, faster, and more effective alternative that could dramatically improve patient outcomes and reduce healthcare costs. If successful, it may become the new standard of care, benefiting patients, surgeons, and payers by streamlining treatment and delivering superior results.